How J J S Cfo Keeps His Footing On The Patent Cliff Whatfinger On bloomberg chief future officer, j&j cfo joe wolk and ceo joaquin duato tell david gura how the company aims to renew its portfolio through research and development and strategic. Between 2024 and 2030, the largest us pharma companies will lose patent protections on drugs that now account for $180 billion in sales. johnson & johnson has $15 billion in sales at risk of erosion.
Patent Cliff Ppt On bloomberg chief future officer, j&j cfo joe wolk and ceo joaquin duato tell david gura how the company aims to renew its portfolio through research and development and strategic acquisition. On bloomberg chief future officer, j&j cfo joe wolk and ceo joaquin duato tell david gura how the company aims to renew its portfolio through research and development and strategic acquisition. J&j reported second quarter earnings tuesday. the company is under scrutiny by investors as it faces drug patent cliffs. This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. it was written for general public to learn to invest based on facts and not on fantasies or hearsay .
Patent Cliff Ppt J&j reported second quarter earnings tuesday. the company is under scrutiny by investors as it faces drug patent cliffs. This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. it was written for general public to learn to invest based on facts and not on fantasies or hearsay . Johnson & johnson cfo joseph wolk says the company beat expectations in 2023, buoyed by 9% growth in innovative medicine and medical technology in the final quarter. Cfo joe wolk just signaled that 2026 is expected to see better growth than 2025. the company’s sitting on game changing approvals in lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular. J&j signed a voluntary agreement with the trump administration on january 8 to lower drug prices through the trumprx.gov platform in exchange for tariff exemptions on pharmaceutical imports . That said, innovative medicines growth is expected to be “slightly stronger” in the first half of the year, j&j’s cfo wolk said.
Comments are closed.